UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog

By
A A A

UCB SA ( UCBJF ) and Dermira, Inc. announced that they have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

Terms of the Deal

UCB granted an exclusive license to Dermira for the development of Cimzia for psoriasis in the U.S., EU and Canada. Dermira will bear the cost of phase III development of Cimzia for dermatology. If approved, Dermira can commercialize Cimzia in the U.S. and Canada. Though sales will be recorded by UCB, Dermira will receive tiered royalties on sales. Dermira will receive up to $49.5 million and $40 million on the achievement of development/regulatory and tiered commercial milestones, respectively.

Under this deal, UCB invested $5 million in Dermira's equity. It could invest up to an additional $15 million in Dermira's equity financings.

Cimzia is already approved for the treatment of adults suffering from moderately-to-severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis as well as for reducing the signs and symptoms of Crohn's disease. In Europe, Cimzia is approved for an additional indication − active axial spondyloarthritis. In 2013, net sales of Cimzia were €594 million, up 27% y/y.

Our Take

We are positive on UCB's deal with Dermira. Cimzia is an important growth driver for UCB apart from Vimpat and Neupro. The drug, if successfully developed for the treatment of psoriasis, will expand the eligible patient population for the Cimzia while boosting its sales potential.

Investors looking for well-positioned stocks in the health care sector may consider Biogen Idec Inc. ( BIIB ), ANI Pharmaceuticals, Inc. ( ANIP ) and ARIAD Pharmaceuticals, Inc. ( ARIA ). While Biogen and ANI Pharma carry a Zacks Rank #1 (Strong Buy), ARIAD holds a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ANIP , BIIB , ARIA , UCBJF

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

28,902,461
  • $17 ▼ 0.29%
23,340,901
  • $13.65 ▼ 3.81%
22,100,186
  • $76.98 ▼ 2.61%
21,626,399
  • $14.7267 ▼ 0.43%
21,320,099
  • $98.07 ▼ 0.73%
17,247,438
    $16.93 unch
16,462,191
  • $40.63 ▼ 0.29%
16,307,489
  • $100.25 ▼ 0.50%
As of 10/1/2014, 11:06 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com